LFCR Q2 2024 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$30M+37.9% YoY

Gross Profit

$10M33.0% margin

Operating Income

-$1M-4.9% margin

Net Income

$14M47.2% margin

EPS (Diluted)

$0.39

QoQ Revenue Growth

+23.0%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$246M

Total Liabilities

$203M

Stockholders' Equity

$42M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$22M	+37.9%
Gross Profit	$10M	$6M	+75.3%
Operating Income	-$1M	-$5M	+72.3%
Net Income	$14M	-$13M	+211.0%